Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.64 USD | +3.57% | +19.65% | +24.57% |
Mar. 13 | Top Premarket Decliners | MT |
Mar. 12 | JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating | MT |
Financials (USD)
Sales 2024 * | 3.15M | Sales 2025 * | 8.12M | Capitalization | 472M |
---|---|---|---|---|---|
Net income 2024 * | -164M | Net income 2025 * | -238M | EV / Sales 2024 * | 150 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 58.1 x |
P/E ratio 2024 * |
-2.95
x | P/E ratio 2025 * |
-2.13
x | Employees | 157 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.46% |
Latest transcript on iTeos Therapeutics, Inc.
1 day | +6.64% | ||
1 week | +18.97% | ||
Current month | +22.97% | ||
1 month | +20.05% | ||
3 months | +22.40% | ||
6 months | +14.42% | ||
Current year | +20.27% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 12-03-31 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 20-05-31 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 20-05-31 |
David Hallal
CHM | Chairman | 57 | 18-05-31 |
Director/Board Member | 52 | 18-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.13% | 29 M€ | -0.55% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 13.64 | +3.57% | 489 885 |
24-03-27 | 13.17 | +6.64% | 595,799 |
24-03-26 | 12.35 | +8.81% | 378,813 |
24-03-25 | 11.35 | +1.43% | 178,911 |
24-03-22 | 11.19 | -1.84% | 128,097 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.27% | 472M | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.86% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |